The goal of this study is to assess the cost-effectiveness of monitoring endoxifen serum concentrations and subsequent personalized dosing of tamoxifen in patients with ERα-positive breast cancer treated with tamoxifen in the adjuvant setting in the Netherlands. This evidence concerns the gene ESR1 and breast cancer.